Protara Therapeutics, Inc.
TARA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $341 | $0 | $0 |
| Gross Profit | $0 | -$341 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $31,704 | $24,785 | $16,808 | $21,088 |
| G&A Expenses | $17,450 | $18,624 | $20,737 | $26,401 |
| SG&A Expenses | $17,450 | $18,624 | $20,737 | $26,401 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$137 | $29,517 | $0 |
| Operating Expenses | $49,154 | $43,272 | $67,062 | $47,489 |
| Operating Income | -$49,154 | -$43,613 | -$67,062 | -$47,489 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4,558 | $3,193 | $1,110 | $237 |
| Pre-Tax Income | -$44,596 | -$40,420 | -$65,952 | -$47,252 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$44,596 | -$40,420 | -$65,952 | -$47,252 |
| % Margin | – | – | – | – |
| EPS | -2.17 | -3.57 | -5.86 | -4.2 |
| % Growth | 39.2% | 39.1% | -39.5% | – |
| EPS Diluted | -2.17 | -3.57 | -5.86 | -4.2 |
| Weighted Avg Shares Out | 20,593 | 11,331 | 11,260 | 11,233 |
| Weighted Avg Shares Out Dil | 20,593 | 11,331 | 11,260 | 11,233 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,135 | $2,727 | $1,110 | $237 |
| Interest Expense | $0 | $0 | $1,137 | $1,737 |
| Depreciation & Amortization | $332 | $341 | $248 | $117 |
| EBITDA | -$48,822 | -$43,272 | -$64,567 | -$45,398 |
| % Margin | – | – | – | – |